BioCentury | Feb 7, 2011
Finance

Savient reloads to go it alone

Savient Pharmaceuticals Inc. traded up last week after raising $230 million in a bumped up offering of convertible debt. The deal removed the financing overhang that had dragged down the shares after the company failed...
BioCentury | Feb 7, 2011
Finance

Deep Discounts Continue

Deep discounts continue The final U.S. IPOs in 2010 slashed their deal prices more than in half just before pricing. If the first few IPOs this year are any indication, that pattern will continue. The...
BC Extra | Feb 4, 2011
Financial News

Pacira raises $42M in IPO

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) raised $42 million through the sale of 6 million shares at $7 in an IPO underwritten by Barclays Capital; Piper Jaffray; Wedbush PacGrow Life Sciences; and Brean Murray, Carret. The price...
BioCentury | Jan 24, 2011
Finance

On the road again

On the road again Two biotechs hit the road last week, hoping to sell the first IPOs of the year: oncology company Endocyte Inc. and specialty pain play Pacira Pharmaceuticals Inc. The companies have slated...
BioCentury | Jan 17, 2011
Finance

IPO watch

After filling in offering details in their S-1s last week, oncology company Endocyte Inc. and specialty pain play Pacira Pharmaceuticals Inc. may be among the first IPOs of the year. Endocyte hopes to sell 5.4...
BC Extra | Jan 14, 2011
Financial News

Pacira sets IPO range

Pacira Pharmaceuticals Inc. (Parsippany, N.J.) amended its IPO and hopes to sell 4.3 million shares at $14-$16. A $15 price would raise $63.8 million and value the company at $223.7 million. The offering is underwritten...
BC Extra | Jan 5, 2011
Financial News

Pacira raises $15M in note deal ahead of IPO

Pacira Pharmaceuticals Inc. (Parsippany, N.J.) raised $15 million through the sale of 5% convertible notes in a private placement to MPM Capital; HBM BioVentures; OrbiMed Advisors; and Sanderling. The notes will convert at a price...
BioCentury | Nov 8, 2010
Finance

Blue skies for pain plays

Blue skies for pain plays Specialty pharma Pacira Pharmaceuticals Inc. filed to raise up to $86.3 million in an IPO. The company (formerly Blue Acquisition Corp. ) was formed when it acquired the injectable business of...
BC Extra | Nov 2, 2010
Financial News

Pacira files for IPO

Pacira Pharmaceuticals Inc. (Parsippany, N.J.) filed to raise up to $86.3 million in an IPO underwritten by Barclays Capital; Piper Jaffray; Wedbush PacGrow Life Sciences; and Brean Murray, Carret & Co. In September, Pacira submitted...
BioCentury | Feb 11, 2008
Strategy

Sell high, buy low

PDL BioPharma Inc. may not have gotten what it wanted from its 2005 purchase of ESP Pharma Inc. for $610 million, but ESP's management has done more than well. Last week, ESP's founders came back...
Items per page:
1 - 10 of 71